{"id":7667,"date":"2024-10-28T15:27:18","date_gmt":"2024-10-28T07:27:18","guid":{"rendered":"https:\/\/regask.com\/?p=7667"},"modified":"2024-11-21T09:22:50","modified_gmt":"2024-11-21T01:22:50","slug":"directrices-de-terapia-genica-celular-en-malasia","status":"publish","type":"post","link":"https:\/\/regask.com\/es\/malaysia-cell-gene-therapy-guidelines\/","title":{"rendered":"La NPRA de Malasia inicia una consulta p\u00fablica sobre la ac..."},"content":{"rendered":"<p>El 7 de octubre de 2024, el <a href=\"https:\/\/regask.com\/es\/npra-malasia-publico-un-documento-de-orientacion-y-directrices-sobre-biosimilares\/\">Agencia Nacional de Regulaci\u00f3n Farmac\u00e9utica (NPRA)<\/a> de Malasia anunci\u00f3 el lanzamiento de una consulta p\u00fablica para la segunda edici\u00f3n de la <strong>\u201cDocumento de orientaci\u00f3n y directrices para el registro de productos de terapia celular y g\u00e9nica (CGTP) en Malasia\u201d.<\/strong> La consulta se desarrollar\u00e1 desde<strong> 7 de octubre de 2024 al 7 de noviembre de 2024, <\/strong>Los CGTP, clasificados como productos biol\u00f3gicos seg\u00fan la Ley de Venta de Medicamentos de 1952 y el Reglamento de Control de Medicamentos y Cosm\u00e9ticos de 1984 de Malasia, desempe\u00f1an un papel fundamental en los avances m\u00e9dicos y requieren una supervisi\u00f3n estricta para garantizar su seguridad, eficacia y calidad.<\/p>\n<p>Las principales enmiendas propuestas incluyen:<\/p>\n<ul>\n<li><strong>Perfeccionamiento de la reglamentaci\u00f3n<\/strong>:Ajustes para los CGTP de clase I, incluidas actualizaciones a los marcos regulatorios y de seguridad.<\/li>\n<li><strong>Revisiones de los requisitos de BPM y BPL<\/strong>:Garantizar est\u00e1ndares actualizados para las Buenas Pr\u00e1cticas de Manufactura (BPM) y aclarar los requisitos de las Buenas Pr\u00e1cticas de Laboratorio (BPL).<\/li>\n<li><strong>Actualizaciones de las directrices<\/strong>:Eliminaci\u00f3n de las directrices obsoletas para las buenas pr\u00e1cticas en materia de tejidos (BPT).<\/li>\n<\/ul>\n<p>La consulta involucra a una amplia gama de partes interesadas, incluidos fabricantes de CGTP, compa\u00f1\u00edas farmac\u00e9uticas, asociaciones, profesionales, investigadores y acad\u00e9micos. El documento se alinea con las pautas nacionales e internacionales, como las de la <strong>Organizaci\u00f3n Mundial de la Salud (OMS)<\/strong>, <strong>Conferencia Internacional sobre Armonizaci\u00f3n (ICH)<\/strong>, <strong>FDA de EE.UU.<\/strong>, y <strong>Agencia Europea de Medicamentos (EMA)<\/strong>.<\/p>\n<p>Esta actualizaci\u00f3n refleja el compromiso de Malasia de mantener altos est\u00e1ndares en el campo en constante evoluci\u00f3n de la terapia celular y g\u00e9nica. Para quienes participan, esta consulta representa una oportunidad vital de contribuir al futuro de la regulaci\u00f3n de la terapia celular y g\u00e9nica en el pa\u00eds.<\/p>\n<p>Para obtener m\u00e1s informaci\u00f3n, consulte a RegAsk<\/p>\n<hr \/>","protected":false},"excerpt":{"rendered":"<p>El 7 de octubre de 2024, la Agencia Nacional Reguladora Farmac\u00e9utica (NPRA) de Malasia anunci\u00f3 el inicio de una consulta p\u00fablica para la segunda edici\u00f3n del \u201cDocumento de Orientaci\u00f3n y Directrices para el Registro de Productos de Terapia Celular y G\u00e9nica (CGTP) en Malasia\u201d. La consulta se extender\u00e1 del 7 de octubre de 2024 al 7 de noviembre de 2024 y ofrecer\u00e1 a las partes interesadas la oportunidad de\u2026<\/p>","protected":false},"author":43,"featured_media":7759,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[35],"tags":[507],"class_list":["post-7667","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-biotech-latest-insights","tag-gene-therapy-regulations"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Malaysia Cell &amp; Gene Therapy Guidelines Updated | RegASK<\/title>\n<meta name=\"description\" content=\"Malaysia&#039;s NPRA is updating guidelines for cell and gene therapy products. Stay informed and participate in the public consultation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/es\/directrices-de-terapia-genica-celular-en-malasia\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Malaysia&#039;s NPRA Begins Public Consultation on Updated Guidelines for Cell and Gene Therapy Products\" \/>\n<meta property=\"og:description\" content=\"Malaysia&#039;s NPRA is updating guidelines for cell and gene therapy products. Stay informed and participate in the public consultation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/es\/directrices-de-terapia-genica-celular-en-malasia\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-28T07:27:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-21T01:22:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/malaysia-npra-begins-public-consultation-updated-guidelines-cell-gene-therapy-products.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Reva Ananda\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Reva Ananda\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/malaysia-cell-gene-therapy-guidelines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/malaysia-cell-gene-therapy-guidelines\\\/\"},\"author\":{\"name\":\"Reva Ananda\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\"},\"headline\":\"Malaysia&#8217;s NPRA Begins Public Consultation on Upd&hellip;\",\"datePublished\":\"2024-10-28T07:27:18+00:00\",\"dateModified\":\"2024-11-21T01:22:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/malaysia-cell-gene-therapy-guidelines\\\/\"},\"wordCount\":255,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/malaysia-cell-gene-therapy-guidelines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/malaysia-npra-begins-public-consultation-updated-guidelines-cell-gene-therapy-products.png\",\"keywords\":[\"Gene Therapy Regulations\"],\"articleSection\":[\"Pharma and Biotech\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/malaysia-cell-gene-therapy-guidelines\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/malaysia-cell-gene-therapy-guidelines\\\/\",\"name\":\"Malaysia Cell & Gene Therapy Guidelines Updated | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/malaysia-cell-gene-therapy-guidelines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/malaysia-cell-gene-therapy-guidelines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/malaysia-npra-begins-public-consultation-updated-guidelines-cell-gene-therapy-products.png\",\"datePublished\":\"2024-10-28T07:27:18+00:00\",\"dateModified\":\"2024-11-21T01:22:50+00:00\",\"description\":\"Malaysia's NPRA is updating guidelines for cell and gene therapy products. Stay informed and participate in the public consultation.\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/malaysia-cell-gene-therapy-guidelines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/regask.com\\\/malaysia-cell-gene-therapy-guidelines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/malaysia-npra-begins-public-consultation-updated-guidelines-cell-gene-therapy-products.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/malaysia-npra-begins-public-consultation-updated-guidelines-cell-gene-therapy-products.png\",\"width\":800,\"height\":600,\"caption\":\"Malaysia Npra Begins Public Consultation Updated Guidelines Cell Gene Therapy Products\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\",\"name\":\"Reva Ananda\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Actualizaci\u00f3n de las directrices de terapia celular y g\u00e9nica de Malasia | RegASK","description":"La NPRA de Malasia est\u00e1 actualizando las directrices para productos de terapia celular y g\u00e9nica. Mant\u00e9ngase informado y participe en la consulta p\u00fablica.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/es\/directrices-de-terapia-genica-celular-en-malasia\/","og_locale":"es_ES","og_type":"article","og_title":"Malaysia's NPRA Begins Public Consultation on Updated Guidelines for Cell and Gene Therapy Products","og_description":"Malaysia's NPRA is updating guidelines for cell and gene therapy products. Stay informed and participate in the public consultation.","og_url":"https:\/\/regask.com\/es\/directrices-de-terapia-genica-celular-en-malasia\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2024-10-28T07:27:18+00:00","article_modified_time":"2024-11-21T01:22:50+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/malaysia-npra-begins-public-consultation-updated-guidelines-cell-gene-therapy-products.png","type":"image\/png"}],"author":"Reva Ananda","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Reva Ananda","Est. reading time":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/malaysia-cell-gene-therapy-guidelines\/#article","isPartOf":{"@id":"https:\/\/regask.com\/malaysia-cell-gene-therapy-guidelines\/"},"author":{"name":"Reva Ananda","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926"},"headline":"Malaysia&#8217;s NPRA Begins Public Consultation on Upd&hellip;","datePublished":"2024-10-28T07:27:18+00:00","dateModified":"2024-11-21T01:22:50+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/malaysia-cell-gene-therapy-guidelines\/"},"wordCount":255,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/malaysia-cell-gene-therapy-guidelines\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/malaysia-npra-begins-public-consultation-updated-guidelines-cell-gene-therapy-products.png","keywords":["Gene Therapy Regulations"],"articleSection":["Pharma and Biotech"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/regask.com\/malaysia-cell-gene-therapy-guidelines\/","url":"https:\/\/regask.com\/malaysia-cell-gene-therapy-guidelines\/","name":"Actualizaci\u00f3n de las directrices de terapia celular y g\u00e9nica de Malasia | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/malaysia-cell-gene-therapy-guidelines\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/malaysia-cell-gene-therapy-guidelines\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/malaysia-npra-begins-public-consultation-updated-guidelines-cell-gene-therapy-products.png","datePublished":"2024-10-28T07:27:18+00:00","dateModified":"2024-11-21T01:22:50+00:00","description":"La NPRA de Malasia est\u00e1 actualizando las directrices para productos de terapia celular y g\u00e9nica. Mant\u00e9ngase informado y participe en la consulta p\u00fablica.","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/malaysia-cell-gene-therapy-guidelines\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/regask.com\/malaysia-cell-gene-therapy-guidelines\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/malaysia-npra-begins-public-consultation-updated-guidelines-cell-gene-therapy-products.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/malaysia-npra-begins-public-consultation-updated-guidelines-cell-gene-therapy-products.png","width":800,"height":600,"caption":"Malaysia Npra Begins Public Consultation Updated Guidelines Cell Gene Therapy Products"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"El sistema operativo de IA regulatoria para equipos de alto rendimiento","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926","name":"Reva Ananda"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/7667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/comments?post=7667"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/7667\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media\/7759"}],"wp:attachment":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media?parent=7667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/categories?post=7667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/tags?post=7667"}],"curies":[{"name":"Gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}